CTOs on the Move

Cloudleaf

www.cloudleaf.com

 
Cloudleaf’s mission is to create significant value across the end-to-end supply chain network from supplier to manufacturing to distribution by dramatically increasing visibility of asset movement, location and condition. Cloudleaf customers gain insights that reduce material losses and enhance the reliability of operations and significantly increase revenues. Cloudleaf customers achieve improvements in supply chain visibility of as much as 5x; first-year return-on-investment of as much as 70x; and annualized value in the tens of millions of dollars.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cloudleaf.com
  • 2550 Great America Way Suite 301
    Santa Clara, CA USA 95052
  • Phone: 408.883.9883

Executives

Name Title Contact Details

Funding

Cloudleaf raised $26M on 08/07/2019

Similar Companies

Advanced Control Technology

Advanced Control Technology is a Shakopee, MN-based company in the Business Services sector.

Don Pepe's Cuban Cafe

Don Pepe's Cuban Cafe is a Altamonte Springs, FL-based company in the Business Services sector.

20nine Design Studios

20nine Design Studios is a Conshohocken, PA-based company in the Business Services sector.

Federal Business Council

Federal Business Council is a Annapolis Junction, MD-based company in the Business Services sector.

Oculis

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.